tiprankstipranks
Protagonist Therapeutics Inc (PTGX)
NASDAQ:PTGX
US Market
PTGX
Protagonist Therapeutics
RESEARCH TOOLSreports
Want to see PTGX full AI Analyst Report?

Protagonist Therapeutics (PTGX) Stock News & Sentiment

739 Followers
Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
Premium
Ratings
Protagonist Therapeutics: Icotyde’s Rapid Psoriasis Uptake and Multibillion‑Dollar Peak Sales Potential Support Buy Rating and Higher $121 Target
1M ago
PTGX
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
Premium
Ratings
Icotyde’s Strong Approval Outlook and Protagonist’s Strengthening Royalties Underpin Buy Rating and $117 Target
2M ago
PTGX
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
Premium
TipRanks Newswire
Entera Bio Moves Toward Phase 3 With Oral Therapy That Could Transform Osteoporosis Treatment (NASDAQ: ENTX)
3M ago
AZN
IBO
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
Premium
Company Announcements
Regulatory Turbulence: FDA Disruptions and U.S. Government Shutdown Threaten Protagonist Therapeutics’ Development Timelines
3M ago
PTGX
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
Premium
Ratings
Protagonist Therapeutics: Near-Term Cash Windfall and Strategic Partnerships Underpin Buy-Rated, Self-Funded Growth Story
3M ago
PTGX
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
Premium
Ratings
Protagonist Therapeutics: Late-Stage Pipeline Strength and Rusfertide Economics Drive Buy Rating and $100 Price Target
3M ago
PTGX
Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
Premium
Ratings
Protagonist Therapeutics: Advancing Multi-Asset Inflammation and Obesity Pipeline with Strong Cash Runway Supports Buy Rating
4M ago
PTGX
More PTGX News >

PTGX News on the Web

STATE STREET CORP Reduces Stake in Protagonist Therapeutics Inc
GuruFocus News
Bearish
Analysts Offer Insights on Healthcare Companies: Adlai Nortye Ltd. Sponsored ADR (ANL), Protagonist Therapeutics (PTGX) and Nuvalent (NUVL)
TipRanks News
Bullish
Top Executive Moves Millions in Major Protagonist Therapeutics Stock Sale
TipRanks News
Bullish
Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), Protagonist Therapeutics (PTGX)
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $130 from $125 at Citi
TipRanks News
Bullish
Protagonist Therapeutics (PTGX) Receives a Buy from Citi
TipRanks News
Neutral
Protagonist Therapeutics price target raised to $137 from $120 at Citizens
TipRanks News
Bullish
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
PTGX
Sector Average
Media Buzz
This Week1 articles
Weekly Average4.75 articles
News Sentiment
This Week19%
Sector Average78%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is PTGX’s Media Buzz Sentiment?
1 articles about PTGX were published this week. In an average week, 4.75 articles are published.
    What is PTGX’s weekly average amount of articles?
    In an average week, 4.75 articles about PTGX are published.
      What is PTGX’s News Sentiment?
      19% of articles about PTGX were positive this week, compared to its sector average of 78%.
        Healthcare Stocks that are Trending in the News
        GOSSGossamer Bio
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        ILAIsland Pharmaceuticals Ltd
        TLSATiziana Life Sciences
        Showing the stocks with the most bullish news sentiment over the past week